Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 12, 2019 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,650 | -- | -- | |
| Jul 12, 2019 | EVP and CFO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 20,000 | -- | -- | |
| Jul 12, 2019 | SVP/GM, Global Vascular | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 30,000 | -- | -- | |
| Jul 12, 2019 | SVP and General Counsel | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,894 | -- | -- | |
| Jun 28, 2019 | Director | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,650 | -- | -- | |
| May 31, 2019 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,650 | -- | -- | |
| Feb 01, 2019 | SVP and GM of Oncology | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- | |
| Feb 01, 2019 | SVP and GM of Oncology | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- | |
| Feb 01, 2019 | SVP and GM of Oncology | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- | |
| Feb 01, 2019 | SVP and GM of Oncology | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.